Woodstock Corp Has $9.14 Million Stake in Eli Lilly and Company $LLY

Woodstock Corp lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 18.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,972 shares of the company’s stock after purchasing an additional 1,825 shares during the quarter. Woodstock Corp’s holdings in Eli Lilly and Company were worth $9,135,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. StrongBox Wealth LLC raised its holdings in shares of Eli Lilly and Company by 3.3% in the third quarter. StrongBox Wealth LLC now owns 2,052 shares of the company’s stock valued at $1,566,000 after purchasing an additional 66 shares during the last quarter. Ransom Advisory Ltd increased its stake in Eli Lilly and Company by 112.9% in the 3rd quarter. Ransom Advisory Ltd now owns 2,451 shares of the company’s stock valued at $1,870,000 after buying an additional 1,300 shares during the last quarter. Family Legacy Financial Solutions LLC lifted its position in Eli Lilly and Company by 2.2% during the 3rd quarter. Family Legacy Financial Solutions LLC now owns 8,783 shares of the company’s stock worth $6,701,000 after buying an additional 190 shares in the last quarter. Threadgill Financial LLC boosted its stake in shares of Eli Lilly and Company by 16.7% during the 3rd quarter. Threadgill Financial LLC now owns 350 shares of the company’s stock worth $267,000 after buying an additional 50 shares during the last quarter. Finally, Grant Private Wealth Management Inc grew its holdings in shares of Eli Lilly and Company by 118.8% in the 3rd quarter. Grant Private Wealth Management Inc now owns 954 shares of the company’s stock valued at $728,000 after acquiring an additional 518 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Wolfe Research boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Four research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Buy” and an average target price of $1,141.73.

Eli Lilly and Company Trading Down 1.2%

LLY stock opened at $1,042.06 on Thursday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The stock has a market cap of $985.14 billion, a price-to-earnings ratio of 50.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. The company has a fifty day moving average price of $951.95 and a two-hundred day moving average price of $826.51. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.